Familial Hypercholesterolemia

Algorithm to identify patients with familial hypercholesterolemia from large health-care encounter databases.

PHILADELPHIA — Patients with heterozygous familial hypercholesterolemia who were treated with inclisiran had reductions in LDL at 510 days and at an average of the period between 90 days and 540 days independent of their underlying genotype, according to results of the ORION-9 trial presented at the American Heart Association Scientific Sessions.

ATLANTA — Information from research, advocacy and education is needed to potentially change the care of patients with familial hypercholesterolemia, according to a presentation at the FH Foundation’s FH Global Summit.

ATLANTA — In this video exclusive, Daniel J. Rader, MD, chair of the department of genetics, chief of the division of translational medicine and human genetics, the Seymour-Gray Professor of Molecular Medicine at the University of Pennsylvania Perelman School of Medicine and chief science adviser for the FH Foundation, spoke with Katherine Wilemon, founder and CEO of the FH Foundation, about major takeaways from the FH Foundation’s FH Global Summit, which focused on familial hypercholesterolemia as a driver for precision public health.

ATLANTA — In this video exclusive, Amy L. Peterson, MD, director of pediatric preventive cardiology and associate professor of pediatrics in the division of pediatric cardiology at the University of Wisconsin School of Medicine and Public Health in Madison, discusses her presentation at the FH Foundation’s FH Global Summit, which focused on her team’s research on cholesterol screening, especially in children to diagnose conditions like FH.

ATLANTA — In this video exclusive, Laura L. Hayman, PhD, FN, FAAN, FAHA, professor in the department of nursing at the University of Massachusetts Boston College of Nursing and Health Sciences, discussed her presentation on primary and primordial prevention of CVD in children, with a strong emphasis on strategies to use in schools, at the FH Foundation’s FH Global Summit.

ATLANTA — Some progress has been made in increasing the knowledge and awareness of FH among general practitioners, cardiologists and other specialists, although more needs to be done to increase these efforts, according to a presentation at the FH Foundation’s FH Global Summit.

ATLANTA — Similar disparities with regards to CVD are also seen in patients with familial hypercholesterolemia, and more work needs to be done to bring awareness and more research into this area, according to a presentation at the FH Foundation’s FH Global Summit.

ATLANTA — Despite the improvements that have been made in cholesterol reduction, more efforts are needed to improve usage rates of cholesterol-lowering medications in patients, including those with familial hypercholesterolemia, according to a presentation at the FH Foundation’s FH Global Summit.

ATLANTA — A machine learning model was able analyze large health-care encounter databases to identify patients with familial hypercholesterolemia, according to data presented at the FH Foundation’s FH Global Summit.